100072-54-6

Basic information

• Product Name: 4-N-Maleimidophenyl butanoic acid
• Synonyms: 4-N-Maleimidophenyl butanoic acid
• CAS NO: 100072-54-6
• Molecular Formula: C₁₄H₁₃NO₄
• Molecular Weight: 259.2573
• Mol File: 100072-54-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 456.194 °C at 760 mmHg
• Flash Point: 229.698 °C
• Appearance: /
• Density: 1.354 g/cm³
• PKA: 4.73±0.10(Predicted)
• CAS DataBase Reference: 4-N-Maleimidophenyl butanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-Maleimidophenyl butanoic acid(100072-54-6)
• EPA Substance Registry System: 4-N-Maleimidophenyl butanoic acid(100072-54-6)

Safety Data

• Hazardous Substances Data: 100072-54-6(Hazardous Substances Data)

Usage

General Description

4-N-Maleimidophenyl butanoic acid is a chemical compound used in various biological and chemical applications. It contains a maleimide group, making it a versatile reagent for modifying proteins and other biomolecules through crosslinking and conjugation. 4-N-Maleimidophenyl butanoic acid is often used in the development of drug delivery systems, bioconjugation techniques, and in the study of protein-protein interactions. Additionally, 4-N-Maleimidophenyl butanoic acid has been utilized in the production of fluorescent labels and in the creation of bioactive compounds for pharmaceutical research. Its unique properties and reactivity make it a valuable tool in the fields of biochemistry, pharmacology, and materials science.

Upstream product

• 108-31-6 maleic anhydride 
• 15118-60-2 4-(4-aminophenyl)butyric Acid 

Relevant articles and documents

Elastic targeting polypeptide-based medicine-carrying nanoparticle as well as preparation method and application thereof

The invention discloses an elastic targeting polypeptide-based medicine-carrying nanoparticle. The nanoparticle is prepared from an elastic targeting polypeptide and a modified medicine, wherein the modified medicine is a modified paclitaxel PTX-LEV-MECH or modified salinomycin Sail-ABA-MPBH. The elastic targeting polypeptide-based medicine-carrying nanoparticle provided by the invention is 100nmor below in particle size, so that the dispersion degree is low, the medicine carrying rate is high, and the nanoparticle can be combined with in-vivo albumin for transferring and carrying medicine, and also can be combined with acidic rich cysteine specifically secreted by tumor cells, the drug is concentrated in the acidic environment, the breast cancer in-situ cancer is targeted for killing, and the toxic and side effects of the drug on the whole body are reduced; and the efficacy of treating breast cancer is increased and improved by utilizing the synergistic effect of two nanoparticles, the occurrence of the metastasis of the breast cancer cells through a lymphatic system and a blood system is reduced, and the occurrence of serious complications such as medical-source lymphatic edemacaused by a lymph node sweeping surgery is reduced.